By annette
A new registry-based study from IHE has evaluated if clinical outcomes and health-related quality of life (HRQoL) in Parkinson’s disease differ depending on whether patients meet the so-called 5-2-1 criteria. The criteria, which are based on motor symptoms, aim to identify patients with insufficient symptom control from oral medication. The results indicate a higher disease …
By annette
IHE participates at the conference with a poster presentation on the importance of using the right prices in the U.S., tailoring your analysis to the question at hand. Poster presentation Tailoring Generalized Cost-Effectiveness Analysis (GCEA) to the U.S. Setting: The Importance of Using the Right Prices Name of authors: Willis Michael, Nilsson Andreas and Neslusan Chery Name …
By annette
This IHE report questions the accuracy and reliability of using standardized drug administration tariffs from publicly available price lists, such as the Southern Healthcare Region’s Price List (SSPL) in Sweden, in health economic evaluations. These tariffs include unrelated costs (such as the drugs themselves, accounting for up to 76% of the total cost), lack granularity, …
By annette
At the 14th Baltic Hematology Conference, Thomas Hofmarcher gave a presentation about findings from the IHE Report “Comparator Report on Cancer in Europe 2025“. The presentation focused on the Baltic countries and hematology. Spending on cancer care, uptake of new medicines, and survival outcomes of cancer patients are all below the EU-average in the three …
By annette
Cancer Patients Europe (CPE) organized a high-level event at the European Parliament on 23rd April hosted by MEP Tomislav Sokol to mark the launch of “the Call to Action: 5 Ways to Reduce Cancer Care Inequalities in Europe”. IHE contributed to the evidence base of this Call to Action through the IHE Report on “Tackling …
By annette
The report analyzes and compares the cancer situation in Europe. It provides a comprehensive view of the development of cancer between 1995 and 2023. Read more
By annette
On March 10th, Oskar Frisell assumed the role of co-chair for health economics at Genomic Medicine Sweden (GMS). He brings extensive experience in health economics research, with a particular focus on precision medicine and precision health. In his new role at GMS, Oskar will apply his expertise in areas such as cost-effectiveness analysis and policy …
By annette
In PharmacoEconomics on the heterogeneity in comparative economic analysis, with specific considerations for the decentralized US Setting and patient-centered care. Read more and download the article
By annette
The Swedish Institute for Health Economics welcomes David Gabrielsson who joined our team this week. David works as an Analyst at our Stockholm office.
By annette
This retrospective population-based study used Swedish registers with health-data on patients with BC/RCC and matched controls with diabetes but no cancer. The high prevalence of diabetes and increased use of systemic corticosteroid treatment observed in this large national study highlights the need for specific clinical management, risk-assessment, and monitoring of individuals with BC/RCC and diabetes. …